| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
ODN 1018 sodium targets Toll-like receptor 9 (TLR9), a pattern recognition receptor that recognizes unmethylated CpG DNA motifs. As a TLR9 agonist, it activates the innate immune system through the MyD88-dependent signaling pathway, leading to the production of pro-inflammatory cytokines and type I interferons. By engaging TLR9, ODN 1018 sodium functions as an immune modulator that enhances antigen-specific immune responses. This mechanism underlies its adjuvant activity and its ability to augment CD8+ T cell responses.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that ODN 1018 sodium functions as a TLR9 agonist and immune modulator. It activates TLR9 signaling in immune cells, leading to the production of pro-inflammatory cytokines and type I interferons. The compound exhibits adjuvant activity in vitro by enhancing immune cell activation and promoting antigen presentation. ODN 1018 sodium augments CD8+ T cell responses when used in combination with LNP-encapsulated OVA peptides. Detailed in vitro activity data, including specific EC50 values, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of ODN 1018 sodium has been demonstrated in animal models of allergic airway inflammation, where it triggers sustained suppression of inflammatory responses. As a TLR9 agonist, it modulates immune responses through activation of the innate immune system. The compound exhibits adjuvant activity in vivo, enhancing antigen-specific immune responses when co-administered with vaccines or antigens. ODN 1018 sodium can be used for research of allergic asthma and systemic lupus erythematosus. Detailed in vivo efficacy data, including dose-response relationships, are not extensively documented.
|
| Enzyme Assay |
The in vitro receptor binding assay for ODN 1018 sodium typically involves measuring its agonistic activity at Toll-like receptor 9 (TLR9). Cell-based reporter assays using HEK293 cells expressing human TLR9 and an NF-κB-driven luciferase reporter are commonly employed. Cells are treated with varying concentrations of ODN 1018 sodium, and TLR9 activation is measured by luciferase activity. Standard protocols include appropriate controls such as CpG oligonucleotide positive controls and non-CpG negative controls.
|
| Cell Assay |
In vitro cell-based assays for ODN 1018 sodium are conducted using immune cell lines such as dendritic cells, macrophages, or B cells. Cells are treated with the compound at various concentrations, and TLR9 activation is assessed by measuring cytokine production (e.g., IL-6, IL-12, IFN-α) using ELISA or qPCR. Cell surface marker expression (e.g., CD80, CD86, MHC class II) is evaluated by flow cytometry to assess immune cell activation. Standard protocols include appropriate positive and negative controls.
|
| Animal Protocol |
In vivo animal studies for ODN 1018 sodium are typically conducted using mouse models of allergic airway inflammation or autoimmune disease. Animals are administered the compound via subcutaneous, intraperitoneal, or intranasal routes at various doses, and efficacy is evaluated by measuring inflammatory markers, cytokine levels, and histopathological changes in tissues. For adjuvant studies, animals are co-administered ODN 1018 sodium with antigens, and antigen-specific immune responses are assessed by measuring antibody titers and T cell responses.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ODN 1018 sodium include its formulation as an oligodeoxynucleotide sodium salt. The compound has a purity of 97.49%. As a nucleic acid-based compound, it is subject to degradation by nucleases in biological fluids. Storage recommendations include standard conditions for oligonucleotides. Detailed pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not extensively documented in the available literature. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for ODN 1018 sodium is limited in the available literature. As a TLR9 agonist, it may induce inflammatory responses that could lead to dose-dependent toxicity. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed acute or chronic toxicity data are available from the search results.
|
| Additional Infomation |
ODN 1018 sodium (1018 ISS sodium) is a TLR9 agonist and immune modulator with adjuvant activity. It triggers sustained suppression of allergic airway inflammation and can be used for research of allergic asthma and systemic lupus erythematosus. The compound has a sequence of 5′-TGACTGTGAACGTTCGAGATGA-3′. It is intended for research use only and is not for human therapeutic applications. It is a controlled substance and not for sale in certain territories.
|
| Molecular Weight |
7655.80
|
|---|---|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1306 mL | 0.6531 mL | 1.3062 mL | |
| 5 mM | 0.0261 mL | 0.1306 mL | 0.2612 mL | |
| 10 mM | 0.0131 mL | 0.0653 mL | 0.1306 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
